{"id":375399,"date":"2022-05-22T16:52:27","date_gmt":"2022-05-22T14:52:27","guid":{"rendered":"https:\/\/innovationorigins.com\/?post_type=selected&amp;p=375399"},"modified":"2022-05-22T16:52:27","modified_gmt":"2022-05-22T14:52:27","slug":"healthplus-ais-mission-to-reduce-the-impact-of-post-surgery-infections-gets-support-from-lumo-labs","status":"publish","type":"selected","link":"https:\/\/ioplus.nl\/archive\/en\/selected\/healthplus-ais-mission-to-reduce-the-impact-of-post-surgery-infections-gets-support-from-lumo-labs\/","title":{"rendered":"Healthplus.ai&#8217;s mission to reduce the impact of post-surgery infections gets support from LUMO Labs"},"content":{"rendered":"\n<p>LUMO Labs is investing in Healthplus.ai\u2019s innovative AI-driven health-tech proposition to reduce the impact of post-operative infections for millions of people across the globe. Lumo has announced the initiative <a href=\"http:\/\/www.lumolabs.io\/\" target=\"_blank\" rel=\"noreferrer noopener\">in a press release<\/a>.<\/p>\n\n\n\n<p>Amsterdam-based Healthplus.ai currently uses artificial intelligence and existing electronic health record data to accurately predict the risk of infection for each individual patient. Ultimately this will also be possible for other post-surgical complications.\u00a0\u00a0<\/p>\n\n\n\n<p>Whereas currently, diagnosis and treatment start after a patient has already developed symptoms, Healthplus.ai AI-driven risk assessment enables more proactive decision-making, monitoring, and treatment, almost immediately after surgery. This is a major improvement to reduce the impact and cost of post-surgery complications.<\/p>\n\n\n\n<p>Infection is a serious post-operative risk for the 300 million patients who undergo surgical procedures each year globally. Data shows that as much as 25 percent, or 75 million people, are diagnosed with infections following surgery. For 25 million of them, these infections cause chronic issues.&nbsp;<\/p>\n\n\n\n<p>Research by Healthplus.ai indicates that an average European hospital spends some 35 million euros per year on the treatment of post-surgical infections.\u00a0\u00a0<\/p>\n\n\n\n<p>\u201cHealthplus.ai moves beyond statistics and accurately predicts side effects and complications of medical treatments for individual patients. This sort of innovation improves healthcare in multiple ways,\u201d said Andy L\u00fcrling, LUMO Labs founding partner. \u201cHealthplus.ai\u2019s technology supports doctors and other medical staff in their treatment planning and decision-making. This will dramatically improve the quality of treatment and therefore the wellbeing of the patients affected.\u201d<\/p>\n\n\n\n<p>\u201cWe are very happy to have found in LUMO Labs the perfect partner to support us in this incredibly exciting and crucial phase of certification and go-to-market,\u201d said Bart Geerts, Healthplus.ai Founder &amp; CEO.<\/p>\n\n\n\n<div class=\"wp-block-stackable-heading stk-block-heading stk-block stk-6c415fa\" id=\"clinical-trials\" data-block-id=\"6c415fa\"><h2 class=\"stk-block-heading__text\">Clinical trials<\/h2><\/div>\n\n\n\n<p>Geerts\u2019 team will use the new investment &#8211; the amount of which was not disclosed &#8211; to finalize the design and build out the first AI software for market release, perform several clinical trials and submit CE 2a certification under MDR.<\/p>\n\n\n\n<p>\u201cThe safety and performance requirements for CE certification of a medical device are understandably high,\u201d said Bart Steverink, Healthplus.ai CTO. \u201cThe funding will help us bring the team, product, and organization to the next level.\u201d<\/p>\n\n\n\n<p>\u201cHealthplus.ai fits LUMO\u2019s investment focus perfectly,\u201d said Sven Bakkes, LUMO Labs founding partner. \u201cAlso the quality of their work and the extremely high level of relevant expertise throughout the entire team weighed heavily in our investment decision. We are happy to have Healthplus.ai onboard and look forward to working with them.\u201d\u00a0<\/p>\n\n\n\n<p>The team already is well established, currently active in the Netherlands, Belgium, Denmark, and Norway. Healthplus.ai recently received a REACT EU grant provided by EFRO of about 1 million euros.<\/p>\n","protected":false},"author":1568,"featured_media":375400,"template":"","meta":{"_acf_changed":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":""},"categories":[34665],"tags":[28722,127791,127793],"location":[6763],"internal_archives":[],"class_list":["post-375399","selected","type-selected","status-publish","has-post-thumbnail","hentry","category-health","tag-healthcare-en","tag-healthplus-ai","tag-lumo-labs-2","location-netherlands"],"blocksy_meta":[],"acf":[],"featured_img":false,"coauthors":[],"author_meta":{"author_link":"https:\/\/ioplus.nl\/archive\/author\/brewbart\/","display_name":"Bart Brouwers"},"relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on May 22, 2022","modified":"Updated on May 22, 2022"},"absolute_dates_time":{"created":"Posted on May 22, 2022 4:52 pm","modified":"Updated on May 22, 2022 4:52 pm"},"featured_img_caption":"","tax_additional":{"category":{"linked":["<a href=\"https:\/\/ioplus.nl\/archive\/en\/category\/health\/\" class=\"advgb-post-tax-term\">Health<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Health<\/span>"],"slug":"category","name":"Categories"},"post_tag":{"linked":["<a href=\"https:\/\/ioplus.nl\/archive\/en\/tag\/healthcare-en\/\" class=\"advgb-post-tax-term\">healthcare<\/a>","<a href=\"https:\/\/ioplus.nl\/archive\/en\/tag\/healthplus-ai\/\" class=\"advgb-post-tax-term\">healthplus.ai<\/a>","<a href=\"https:\/\/ioplus.nl\/archive\/en\/tag\/lumo-labs-2\/\" class=\"advgb-post-tax-term\">LUMO Labs<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">healthcare<\/span>","<span class=\"advgb-post-tax-term\">healthplus.ai<\/span>","<span class=\"advgb-post-tax-term\">LUMO Labs<\/span>"],"slug":"post_tag","name":"Tags"},"language":{"linked":["<a href=\"https:\/\/ioplus.nl\/archive\/en\/\" class=\"advgb-post-tax-term\">EN<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">EN<\/span>"],"slug":"language","name":"Tags"},"post_translations":{"linked":["<a href=\"https:\/\/ioplus.nl\/archive\/?taxonomy=post_translations&#038;term=pll_628a4f9fa465c\" class=\"advgb-post-tax-term\">pll_628a4f9fa465c<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">pll_628a4f9fa465c<\/span>"],"slug":"post_translations","name":""},"location":{"linked":["<a href=\"https:\/\/ioplus.nl\/archive\/location\/netherlands\/\" class=\"advgb-post-tax-term\">Netherlands<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Netherlands<\/span>"],"slug":"location","name":"Locations"},"internal_archives":{"linked":[],"unlinked":[],"slug":"internal_archives","name":"Internal Archives"}},"series_order":"","_links":{"self":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/selected\/375399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/selected"}],"about":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/types\/selected"}],"author":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/users\/1568"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media?parent=375399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/categories?post=375399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/tags?post=375399"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/location?post=375399"},{"taxonomy":"internal_archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/internal_archives?post=375399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}